RecruitingNCT06714903
Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer
Multi-omics Study of Intestinal Microecology in Patients with Colorectal Cancer Related to Immunotherapy
Sponsor
The First Hospital of Jilin University
Enrollment
50 participants
Start Date
Jul 15, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this observational study is to understand the effect of gut microbiota on the efficacy of immunotherapy in patients with metastatic colorectal cancer and to explore the specific mechanisms of this process. In this way, it provides new ideas for the clinical treatment of colorectal cancer.
Eligibility
Min Age: 35 YearsMax Age: 75 Years
Inclusion Criteria4
- Clinical and pathological diagnosis of metastatic colorectal cancer
- years old (both ends inclusive)
- complete clinical information
- signed informed consent
Exclusion Criteria5
- combined with severe respiratory and circulatory diseases
- combined with other malignant tumors
- recent severe active bleeding, uncontrolled active infection or active peptic ulcer
- moderate to severe renal insufficiency
- other circumstances that are judged by the investigator to be unsuitable for participating in this study
Interventions
OTHERtreatment option-sintilimab plus fruquintinib
sintilimab plus fruquintinib
OTHERtreatment option-fruquintinib alone
fruquintinib alone
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06714903
Related Trials
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
NCT067783821 location
Smart Measurement of Circulating Tumor DNA
NCT069898142 locations
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
NCT062083711 location
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
NCT066437931 location